UC-II Type-II Collagen

Previous studies have shown that undenatured type II collagen (UC-II) is effective in the treatment of rheumatoid arthritis, and preliminary human and animal trials have shown it to be effective in treating osteoarthritis (OA). The present clinical trial evaluated the safety and efficacy of UC-II as compared to a combination of glucosamine and chondroitin (G+C) in the treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious resulting in a significant reduction in all assessments from the baseline at 90 days; whereas, this effect was not observed in G+C treatment group. Specifically, although both treatments reduced the Western Ontario McMaster Osteoarthritis Index (WOMAC) score, treatment with UC-II reduced the WOMAC score by 33% as compared to 14% in G+C treated group after 90 days. Similar results were obtained for visual analog scale (VAS) scores. Although both the treatments reduced the VAS score, UC-II treatment decreased VAS score by 40% after 90 days as compared to 15.4% in G+C treated group. The Lequesne's functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II reduced Lequesne's functional index score by 20% as compared to 6% in G+C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed significant enhancement in daily activities suggesting an improvement in their quality of life.

Positive effects were observed with CII at the lowest dosage tested, and the presence of serum antibodies to CII at baseline may predict response to therapy. No side effects were associated with this novel therapeutic agent. Further controlled studies are required to assess the efficacy of this treatment approach.

Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.

RESULTS: After 120 days of supplementation, subjects in the UC-II group exhibited a statistically significant improvement in average knee extension compared to placebo (81.0 ± 1.3º vs 74.0 ± 2.2º; p = 0.011) and to baseline (81.0 ± 1.3º vs 73.2 ± 1.9º; p = 0.002). The UC-II cohort also demonstrated a statistically significant change in average knee extension at day 90 (78.8 ± 1.9º vs 73.2 ± 1.9º; p = 0.045) versus baseline. No significant change in knee extension was observed in the placebo group at any time. It was also noted that the UC-II group exercised longer before experiencing any initial joint discomfort at day 120 (2.8 ± 0.5 min, p = 0.019), compared to baseline (1.4 ± 0.2 min). By contrast, no significant changes were seen in the placebo group. No product related adverse events were observed during the study. At study conclusion, five individuals in the UC-II cohort reported no pain during or after the stepmill protocol (p = 0.031, within visit) as compared to one subject in the placebo group.

CONCLUSIONS: Daily supplementation with 40 mg of UC-II was well tolerated and led to improved knee joint extension in healthy subjects. UC-II also demonstrated the potential to lengthen the period of pain free strenuous exertion and alleviate the joint pain that occasionally arises from such activities.



http://www.meriva.info/en/meriva-bioavailable-curcumin/scientific-support/ The treadmill performance (10% inclination, 3 Km/h speed) showed an improvement of 201% of the initial walked distance at two months, and a further improvement (+44%) at three months from the beginning of the study.

These positive results were complemented by secondary end-points, namely the decrease in supplemental therapy use (63% in the Meriva® group vs 12% in the treatment group) and the decrease in gastrointestinal complications (38% in Meriva® vs 15% in controls (p<0.05).

Overall, the management costs in the Meriva® group decreased by 49% compared to a non significant 3% decrease for the control group.

  • Felson D.T., et al., Arthr. Reum, 1987, 30: p. 914-918.
  • Belcaro G., et al., Panminerva Medica, 2010, 52(2 Suppl 1): p. 55-62.
  • Belcaro G., Cesarone M.R., Dugall M. et al., Altern Med Rev, 2010, 15(4): p. 337-44.
  • Belcaro, G., et al., Eur Rev Med Pharmacol Sci, 2014. 18(24): p. 3959-63.
  • Pajardi, G., et al., Evid Based Complement Alternat Med, 2014. 2014: p. 891310.


Hyaluronic Acid

Abstract: Hyaluronan (HA) is a component that is particularly abundant in the synovial fluid. Randomized, double-blinded, placebo-controlled trials carried out between 2008 and 2015 have proven the effectiveness of HA for the treatment of symptoms associated with synovitis, and particularly, knee pain, relief of synovial effusion or inflammation, and improvement of muscular knee strength. The mechanism by which HA exerts its effects in the living body, specifically receptor binding in the intestinal epithelia, has gradually been clarified. This review examines the effects of HA upon knee pain as assessed in clinical trials, as well as the mechanism of these effects and the safety of HA.
  • Hatayama T, Nagano M, Yamaguchi N, Kumagai S, Ohnuki K. The effect of a supplement on knee pain and discomfort evaluated by visual analogue scale(VAS): a randomized, double-blind, placebo-controlled study. Kenko-shien. 2008;10:13–7.
  • Kalman DS, Heimer M, Valdeon A, Schwartz H, Sheldon E. Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint®) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial. Nutr. J.. 2008;7
  • Iwaso H, Sato T. Examination of the efficacy and safety of oral administration of Hyabest® (J)-highly-pure hyaluronic acid for knee joint pain. J Jpn Soc Clin. Sports Med. 2009;58:566–72.
  • Sato T, Iwaso H. An Effectiveness study of hyaluronic acid Hyabest® (J) in the treatment of osteoarthritis of the knee on the patients in the United State. J New Rem & Clin. 2009;58:551–8.
  • Möller I, Martinez-Puig D, Chetrit C. Oral administration of a natural extract rich in hyaluronic acid for the treatment of knee OA with synovitis: a retrospective cohort study. Clin Nutr Suppl. 2009;4:171–2. doi: 10.1016/S1744-1161(09)70394-1.
  • Nagaoka I, Nabeshima K, Murakami S, Yamamoto T, Watanabe K, Tomonaga A, et al. Evaluation of the effects of a supplementary diet containing chicken comb extract on symptoms and cartilage metabolism in patients with knee osteoarthritis. Exp Ther Med. 2010;1:817–27.
  • Yoshimura M, Aoba Y, Watari T, Momomura R, Watanabe K, Tomonaga A, et al. Evaluation of the effect of a chicken comb extract-containing supplement on cartilage and bone metabolism in athletes. Exp Ther Med. 2012;4:577–80.
  • Tashiro T, Seino S, Sato T, Matsuoka R, Masuda Y, Fukui N. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. Sci. World J.. 2012;doi:10.1100/2012/167928.
  • Martinez-Puig D, Möller I, Fernández C, Chetrit C. Efficacy of oral administration of yoghurt supplemented with a preparation containing hyaluronic acid (Mobilee™) in adults with mild joint discomfort: a randomized, double-blind, placebo controlled intervention study. Mediterr J Nutr Metab. 2013;6:63–8. doi: 10.1007/s12349-012-0108-9.
  • Moriña D, Solà R, Valls RM, López de Frutos V, Montero M, Giralt M, et al. Efficacy of a Low-fat Yogurt Supplemented with a Rooster Comb Extract on Joint Function in Mild Knee Pain Patients: A Subject-level Meta-analysis. Ann Nutr Metab. 2013;63:1386.
  • Sánchez J, Bonet ML, Keijer J, van Schothorst EM, Mölller I, Chetrit C, et al. Blood cells transcriptomics as source of potential biomarkers of articular health improvement: effects of oral intake of a rooster combs extract rich in hyaluronic acid. Genes Nutr. 2014;9:417. doi: 10.1007/s12263-014-0417-3.
  • Nelson FR, Zvirbulis RA, Zonca B, Li KW, Turner SM, Pasierb M, et al. The effects of an oral preparation containing hyaluronic acid (Oralvisc®) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses. Rheumatol Int. 2015;35:43–52. doi: 10.1007/s00296-014-3047-6.
  • Jensen GS, Attridge VL, Lenninger MR, Benson KF. Oral intake of a liquid high-molecular-weight hyaluronan associated with relief of chronic pain and reduced use of pain medication: results of a randomized, placebo-controlled double-blind pilot study. J Med Food. 2015;18:95–101. doi: 10.1089/jmf.2013.0174.


Boswellia Serrata

CONCLUSION: Boswellia serrata extract reduces pain and improves physical functioning significantly in osteoarthritis patients; and it is safe for human consumption. 5-Loxin may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in osteoarthritis patients.

Abstract: Osteoarthritis is the most common degenerative joint disease that begins asymptomatically in middle age with progressive symptoms in advancing age. Majority of people by the age 40 years may develop osteoarthritis, especially in weight bearing joints. Females are prone with 25% prevalence, whereas males have a prevalence of 16%. In the present study, 56 patients fulfilling the diagnostic criteria of osteoarthritis, divided into two groups. Patients of first group were administered with 500 mg capsule of boswellia serrata, 6 g per day (in three divided doses) with lukewarm water (n=29) and the second group) capsule boswellia serratas above along with local application of boswellia serrata ointment on the affected joints (n=23). After a course of therapy for 2 months, symptomatic improvement was observed in both the groups at various levels with promising results in the patients of first group.



A clinical study done at St. John’s Medical College, Bangalore, India and published in Planta Medica journal in 1997 provided clinical evidence of piperine’s role in increasing the bioavailability of Curcumin, and has become one of the most downloaded papers of that journal. BioPerine® significantly improved the uptake of Curcumin - the healthful extract from turmeric roots with clinically - validated efficacy in a wide range of health conditions ranging from inflammation to cancer.

Bioavailability of Curcumin (2000 mg) when co - administered with BioPerine® (20 mg) was enhanced by 20 - fold or 2000% compared to bioavailability of curcumin alone at doses that were devoid of adverse side effects.
  • Rao VR, et al. Simultaneous determination of bioactive compounds in Piper nigrum L. and a species comparison study using HPLC-PDA. Nat Prod Res. (2011)
  • Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. (1998)
  • Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol. (2011)
  • Lack of Adverse Influence of Black Pepper, Its Oleoresin and Piperine in the Weanling Rat.
  • Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. (2007)